Background Bivalirudin is an alternative accepted therapy to unfractionated heparin for
patients with myocardial infarction (MI) undergoing percutaneous coronary intervention …

Bivalirudin has gained ground against unfractionated heparin (UFH) in percutaneous
coronary interventions (PCI), due to a reported better safety profile. However, whether …

Background: This meta-analysis is to evaluate the efficacy and safety of bivalirudin in
patients with ST-elevation myocardial infarction (STEMI). Methods: PubMed, Cochrane …

Background The efficacy and safety of bivalirudin versus heparin in patients undergoing
percutaneous coronary intervention (PCI) 1 remains controversial in to date. Our meta …

Introduction and objectives Contrasting data have been reported on bivalirudin as an
anticoagulation strategy during percutaneous coronary interventions, offering theoretical …

Background The aim of this study was to assess the impact of bivalirudin, as compared to
unfractionated heparin, on clinical outcomes in patients with ST‐segment elevation …

Bivalirudin, a direct thrombin inhibitor, was developed as an antithrombin agent for patients
undergoing percutaneous coronary interventions (PCI) with the hypothesis that it would …

Background The aim of the study was to compare the efficacy and safety of bivalirudin
versus unfractionated heparin (UFH) in patients with acute myocardial infarction who …

It has been shown that bleeding complications are associated with higher mortality rates
among patients undergoing coronary angioplasty. Due to its properties, bivalirudin may …

Recent data suggest that bivalirudin, a reversible direct thrombin inhibitor, may be
noninferior to heparins (unfractionated heparin/low molecular weight heparin) in providing …